Capital Bank & Trust’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Capital Bank & Trust’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-25,000	Closed	-$17K	–	392
2020 Q4	$17K	Sell	25,000 -240	-1%	-$511	﹤0.01%	359
2020 Q3	$57K	Hold	25,240	–	–	﹤0.01%	308
2020 Q2	$90K	Hold	25,240	–	–	﹤0.01%	292
2020 Q1	$96K	Hold	25,240	–	–	﹤0.01%	349
2019 Q4	$76K	Buy	+25,240	New	+$65.6K	﹤0.01%	395

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Capital Bank & Trust's BMY.RT Position: Q1 2021 in Review

Capital Bank & Trust sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 25,000 shares — an estimated $17K sold.

Capital Bank & Trust first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $96K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Capital Bank & Trust reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Capital Bank & Trust sold 25,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $17K.
Capital Bank & Trust first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Capital Bank & Trust's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $96K in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Capital Bank & Trust's 13F filing for Q1 2021, filed 14 May 2021.